# Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC Esophageal Cancer

> **NCT02857218** · EARLY_PHASE1 · WITHDRAWN · sponsor: **OHSU Knight Cancer Institute**

## Conditions studied

- Stage IIB Esophageal Cancer AJCC v7
- Stage III Esophageal Cancer AJCC v7
- Stage IIIA Esophageal Cancer AJCC v7
- Stage IIIB Esophageal Cancer AJCC v7
- Stage IIIC Esophageal Cancer AJCC v7

## Interventions

- **DRUG:** Ferumoxytol
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT02857218
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2018-04-27
- **Primary completion:** 2021-08-19
- **Final completion:** 2021-08-19
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Inadequate enrollment
- **Last updated:** 2021-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02857218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02857218, "Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC Esophageal Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02857218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*